Novel multidrug resistance modulators, KR-30026 and KR-30031, in cancer cells

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4577-4582

  Choi, Sang Un ^a   Lee, Byung Ho ^a   Kim, Kwang Hee ^a   Choi, Eun Jung ^a   Park, Sung Hee ^a   Shin, Hwa Sup ^a   Yoo, Sung Eun ^a   Jung, Noh Pal ^b   Lee, Chong Ock ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

KR 30026; KR 30031; Multidrug resistance; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; KR 30026; KR 30031; PACLITAXEL; RHODAMINE; TAMOXIFEN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL TISSUE; AORTA; ARTICLE; CANCER CELL; CARDIOTOXICITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; GUINEA PIG; HEART LEFT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE TONE;

ANIMALS; AORTA, THORACIC; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; GUINEA PIGS; HEART; HUMANS; KINETICS; MALE; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINES; TUMOR CELLS, CULTURED; VASODILATION; VERAPAMIL;

EID: 0031418812     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Morrow CS and Cowan KH: Mechanisms and clinical significance of multidrug resistance. Oncology 2: 55-63, 1988.
2. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transpoter. Annu Rev Biochem 62: 385-427, 1993.
3. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Robinson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
4. Campling BG, Young LC, Beer KA, Lam Y, Deeley RG, Cole SPC and Gerlach JH: Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3: 115-122, 1997.
5. Gerlach JH, Endicott JA, Juranka PF, Herderson G, Sarangi F, Deuchars KL and Ling V: Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a model for multidrug resistance. Nature (Lond.) 324: 485-489, 1986.
6. Chaudhary PM and Robinson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94, 1991.
7. Thorgeirsson SS, Silverman JA, Gant TW and Marino PA: Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther 49: 283-292, 1991.
8. Lum BL, Gosland MP, Kaubisch S and Sikic BI: Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109, 1993.
9. Leyland-Jones B, Dalton W, Fisher GA and Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. Cancer Suppl 72: 3484-3488, 1993.
10. Harker WG and Sikic BI: Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res 46: 2369-2373, 1986.
11. Tsuruo T, Lida H, Tsukagoshi S and Sakurai, Y: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
12. Benson AB, Trump DL, Koeller JM, Egorin MI, Olman EA and Witte RS: Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 69: 781-795, 1985.
13. Gottesman MM and Pastan I: Clinical trials of agents that reverse multidrug resistance. J Clin Oncol 7: 409-411, 1989.
14. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE and Young RC: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641-647, 1987.
15. Tew KD, Houghton PJ and Houghton JA: Modulation of P-glycoprotein-mediated multidrug resistance. In: Preclinical and clinical modulation of anti-cancer drugs (M. A. Hollinger). Boca Raton, Fl: CRC Press, 1983, pp125-197
16. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD and Tew KD: P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine. J Natl cancer Inst 86: 688-694, 1994.
17. Choi SU, Kim NY, Choi EJ, Kim KH and Lee CO: Establishment of doxorubicin resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharm Res 19: 342-347, 1996.
18. Lee J, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT and Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Molecular Pharmacol 46: 627-638, 1994.
19. Iwahashi T, Okochi E, Ono K, Sugawara I, Tsuruo T and Mori S: Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anticancer Res 11: 1309-1312, 1991.